The board of directors of Simcere Pharmaceutical Group Limited announced that, on December 20, 2023, COSELA (Trilaciclib Hydrochloride for Injection), an innovative drug of the Group in the field of oncology, has obtained the Approval Notice of Supplemental Application of Drug issued by the National Medical Products Administration of China (the NMPA). Pursuant to which, it is agreed that G1 Therapeutics Inc. (?G1?) transferred the drug production technology of COSELA to Hainan Simcere Pharmaceutical Co. Ltd. (?G1?) transfer the drug production technology of C OSELA to Hainsan Simcere Pharmaceutical Co.

Ltd. (Hainan Simcere Pharmaceutical Company Ltd., an indirect wholly-owned subsidiary of the Company, and it also issued the Drug Approval Number: H20237181. In the future, COSELA can be produced by the production enterprises of the Group in Haikou, Hainan Province. The localization of this imported innovative drug will further improve its accessibility to patients with cancer in China.